Denali Therapeutics (DNLI) 10-K2021 FY Annual report

Filed: 28 Feb 22, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Aduhelm, anemia, ASO, assay, asymptomatic, baseline, begun, biodistribution, bioresearch, bottom, breast, CA, calendar, Calico, cap, caregiver, CDC, Clinician, Colorado, constitutionality, cortex, cut, Delta, discrimination, divergent, division, Economy, elicited, embedded, embracing, emphasizing, ergonomic, ESCAPE, ethnic, evidenced, extracranial, feedback, female, foot, fostering, ganglioside, Gcase, GlcCer, glucosylceramide, glucosylsphingosine, granule, grit, harassment, highlighted, HIMALAYA, Homology, hone, hotline, hybrid, hypotension, idiopathic, IHC, IIIA, Impression, inactivation, intermediary, intrathecal, IP, IRR, knockdown, Lake, lifted, LIGHTHOUSE, linear, Logan, longest, LUMA, main, male, medium, metastatic, mission, mono, monovalent, MPSII, Northeast, Omicron, online, operationalization, orthostatic, outreach, pace, Pertuzumab, pilot, poor, possession, pre, proper, qualification, racial, reinforced, rescinding, resurgence, root, ROPAD, Rostock, routine, safest, Salt, sanctuary, Sanfilippo, Sep, sequester, serum, SLC, standing, sulfohydrolase, supervisory, suppressed, Switzerland, Symposium, telecommute, telecommuting, top, Trastuzumab, tyrosine, ulcerative, unaddressed, unchanged, Unified, unity, Utah, vaccination, vast, Virginia, Virtual, volunteerism, warehouse, workplace, WORLDSymposium, WORLDSymposiumTM, younger, youngest, Zealand, Zurich

Removed: accrue, advice, Aid, analyze, bargaining, beneficiary, careful, caring, Certified, classification, collective, consolidate, coupon, deducting, define, dosed, expert, formally, Goldman, lessee, lessor, liver, meantime, Morgan, nomination, Nonemployee, optional, overlapping, payroll, preparing, rat, relocate, repeal, retrospective, reversing, Sangamo, scheduled, split, Stanley, stipulated, suffering, traded, underwriting, undisclosed, VIE, waiver, winding

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

DNLI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), I, Ryan J. Watts, Ph.D., President and Chief Executive Officer of Denali Therapeutics Inc. (the “Company”), hereby certify that:

1.The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 28, 2022


By:			/s/ Ryan J. Watts
Name:			Ryan J. Watts, Ph.D.
Title:			President and Chief Executive Officer